Clinical Trials Logo

Short Bowel Syndrome clinical trials

View clinical trials related to Short Bowel Syndrome.

Filter by:

NCT ID: NCT00138879 Completed - Crohn's Disease Clinical Trials

Citrulline: A Plasmatic Marker to Assess and Monitor Small Bowel Crohn's Disease Patients

Start date: May 2003
Phase: N/A
Study type: Observational

Citrulline is an amino acid produced in the intestine and in the liver, but the liver does not contribute significantly to circulating citrulline concentrations. The intestine is thus the only organ that normally releases significant amounts of citrulline into the blood. The investigators have designed a study looking at the value of measuring plasma citrulline concentration in patients with Crohn’s disease and short bowel or normal intestinal length. Measuring the plasma citrulline concentration in short bowel patients may help to distinguish between patients who need permanent parenteral feeding from patients with just transient intestinal dysfunction. It may also help the investigators in understanding the small bowel intestinal length remaining and the absorptive integrity. In patients with normal intestinal length and Crohn’s disease, it may be a reliable marker of small bowel damage and could be applied to establish therapeutic improvements. It has been demonstrated to strongly correlate (inversely) with severity on intestinal biopsies. The investigators hypothesise that the plasma citrulline concentration is a marker for small bowel absorptive integrity and an appropriate surrogate for functional length of the small intestine. Controlled data do not yet exist to establish the place of plasma citrulline in the assessment of small bowel function in man.

NCT ID: NCT00081458 Completed - Clinical trials for Short Bowel Syndrome

Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome

Start date: May 25, 2004
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of teduglutide compared with placebo in subjects with parenteral nutrition (PN)-dependent short bowel syndrome (SBS).

NCT ID: NCT00067860 Completed - Clinical trials for Short Bowel Syndrome

Diet/Growth Factor Mechanisms of Gut Adaptation

Start date: October 1996
Phase: Phase 2
Study type: Interventional

This is a double-blind randomized controlled study on the clinical and metabolic effects and underlying gut mucosal mechanisms of modified diet, with or without recombinant human growth hormone, in adults with severe short bowel syndrome dependent upon parenteral nutrition. Clinical endpoints include ability to wean patients from parenteral feeding, metabolic endpoints include gut nutrient absorptive function and molecular endpoints include expression of growth factors and nutrient transporters in small bowel and colonic mucosa. The 6-month study is performed, in part, in the General Clinical Research Center for inpatient stays and outpatient visits.